8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study)

2019

Journal of Hepatology , Volume 70 - Issue 3 p. 554- 557

Additional Metadata
Persistent URL	doi.org/10.1016/j.jhep.2018.10.032, hdl.handle.net/1765/115183
Journal	Journal of Hepatology
Organisation	Department of Internal Medicine
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Boerekamps, A., Vanwolleghem, T., van der Valk, M, van den Berk, G.E., van Kasteren, M, Posthouwer, D., … Rijnders, B. (2019). 8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study). Journal of Hepatology, 70(3), 554–557. doi:10.1016/j.jhep.2018.10.032

Publication